<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The stromal immunoglobulin kappa chain (IGKC) has been validated as an immunologic biomarker of prognosis and response to therapy in human <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This validation emphasizes the key role of humoral immunity in control of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">cancer progression</z:e> and has major implications for determining prognosis of patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>